182.94

1.76% -3.27

After Hours: 182.94

Axsome Therapeutics Inc (AXSM)

Overview News Price History Option Chain Financials Why AXSM Down? Discussions Forecast

Axsome Therapeutics Inc stock is traded at $182.94, with a volume of 229.72K. It is down -1.76% in the last 24 hours and up +3.46% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Previous Close:

$186.21

Open:

$186.97

24h Volume:

229.72K

Relative Volume:

0.37

Market Cap:

$9.22B

Revenue:

$338.46M

Net Income/Loss:

$-310.96M

P/E Ratio:

-28.02

EPS:

-6.53

Net Cash Flow:

$-132.82M

1W Performance:

+1.16%

1M Performance:

+3.46%

6M Performance:

+73.85%

1Y Performance:

+39.06%

1-Day Range:

$182.69

$186.97

1-Week Range:

$178.00

$187.18

52-Week Range:

$86.99

$191.50

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name

Axsome Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(212) 332-3241

Address

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Employee

816

Twitter

Next Earnings Date

2025-02-18

Latest SEC Filings

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AXSM Axsome Therapeutics Inc	182.94	9.39B	338.46M	-310.96M	-132.82M	-6.53
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-01-25	Initiated	B. Riley Securities	Buy
Sep-03-25	Resumed	Wells Fargo	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Initiated	Oppenheimer	Outperform
Apr-07-25	Initiated	Jefferies	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-31-24	Reiterated	Mizuho	Outperform
Sep-03-24	Initiated	Wells Fargo	Overweight
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy
Jul-22-24	Initiated	Needham	Buy
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-06-24	Initiated	UBS	Buy
Jan-25-24	Initiated	RBC Capital Mkts	Outperform
Dec-13-23	Initiated	Citigroup	Buy
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral
Jan-05-23	Initiated	Piper Sandler	Neutral
Nov-01-22	Initiated	Loop Capital	Buy
Sep-07-22	Resumed	Mizuho	Buy
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-10-21	Initiated	Berenberg	Buy
Jan-08-21	Initiated	Jefferies	Buy
Dec-16-20	Initiated	Mizuho	Buy
Sep-29-20	Initiated	BofA Securities	Underperform
Sep-10-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Reiterated	H.C. Wainwright	Buy
Apr-14-20	Initiated	Cowen	Outperform
Dec-30-19	Reiterated	H.C. Wainwright	Buy
Dec-17-19	Reiterated	H.C. Wainwright	Buy
Dec-16-19	Reiterated	Guggenheim	Buy
Oct-16-19	Initiated	Guggenheim	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-28-19	Initiated	SunTrust	Buy
May-23-19	Reiterated	H.C. Wainwright	Buy
Apr-08-19	Initiated	SVB Leerink	Outperform
Mar-15-19	Reiterated	H.C. Wainwright	Buy
Oct-03-16	Resumed	Brean Capital	Buy
Dec-15-15	Initiated	Cantor Fitzgerald	Buy
Dec-14-15	Initiated	Ladenburg Thalmann	Buy

View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

Feb 12, 2026

Why (AXSM) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Feb 12, 2026

Feb 09, 2026

Axsome Therapeutics (AXSM) Stock Analysis: A 63% Revenue Growth Fuels a Promising Biotech Play - DirectorsTalk Interviews

Feb 09, 2026

Feb 07, 2026

Morgan Stanley Remains Bullish on Axsome (AXSM), Reiterates $190 PT - MSN

Feb 07, 2026

Feb 06, 2026

Should You Buy Axsome Therapeutics Stock Before Feb. 23? - AOL.com

Feb 06, 2026

Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM) - Sahm

Feb 06, 2026

Feb 05, 2026

Principal Financial Group Inc. Acquires 12,923 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Feb 05, 2026

Feb 04, 2026

Hot Picks: Small-cap pharma stocks in focus as key drug approvals near - BNN Bloomberg

Feb 04, 2026

The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Strong Auvelity Sales And Alzheimer’s Label Hopes - Yahoo Finance

Feb 04, 2026

Feb 03, 2026

Axsome Therapeutics says AXS-12 NDA submission on track for January - MSN

Feb 03, 2026

1 High-Flying Stock With More Upside Ahead - Finviz

Feb 03, 2026

Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates - Finviz

Feb 03, 2026

Axsome Therapeutics (NASDAQ:AXSM) Given New $245.00 Price Target at Jefferies Financial Group - MarketBeat

Feb 03, 2026

Axsome Therapeutics (AXSM) reports 66% revenue growth in FY2025, beats analyst estimates - MSN

Feb 03, 2026